New Study Proves CBD Helps with Addiction, Anxiety, Impulsivity
April 23, 2018

New Study Proves CBD Helps with Addiction, Anxiety, Impulsivity

by NCIA Editorial Staff

A new study reveals CBD (cannabidiol) can be used as a treatment in curbing cocaine and alcohol relapse in lab animals. The Neuropsychopharmacology study from Nature Journal serves as further proof that cannabinoids do, in fact, have therapeutic value.

Much of the cannabis-focused scientific community and business owners are well aware of these benefits. However, this study is a welcomed addition to the mounting evidence in favor of treating patients with CBD- as well as calling cannabis medicine.

Mary’s Medicinals is a trusted leader in the therapeutic CBD industry. Their Chief Scientific Officer, Jeremy Riggle Ph.D. isn’t surprised with the study’s outcome but hopeful it may result in human clinical testing in the future. “While the outcome of this study is exciting, there are literally hundreds of other animal/preclinical studies that have demonstrated the potential of CBD for human health,” he said to NCIA in an exclusive interview. He added, “Until the federal government allows comprehensive double blind randomized placebo-controlled studies on human populations these studies will continue to pile up without any action or validation.”

The Executive Director of California marijuana dispensary, A Therapeutic Alternative, agrees its a step in the right direction. “When a study like this comes out it corroborates the decade of anecdotal evidence that I have been seeing first hand,” said Kimberly Cargile. One of the top reasons members come to her shop is to reduce their use of pharmaceuticals, street drugs, alcohol and cigarettes. Her go-to recommendations for new members: CBD products.

Cargile said she sees it as the fastest growing market because anyone can use CBD without the psychoactive effects of products with THC. You can learn more about the differences between THC and CBD as well as how CBD helps patients with debilitating conditions in our recent blog post.  

Facts from the published study:

  • CBD attenuated context-induced and stress-induced drug seeking without tolerance, sedative effects, or interference with normal motivated behavior
  • Following treatment termination, reinstatement remained attenuated up to ≈5 months
  • CBD also reduced experimental anxiety and prevented the development of high impulsivity in rats with an alcohol dependence history

Mary’s customers and patients can shop online for vaping oil, topical muscle freeze, and their CBD-releasing transdermal CBD gel pen – the same method of delivery used by researchers for the new study.

Unlike products with THC, CBD can be shipped across America because CBD is found in industrial hemp. As Dr. Riggle explained, “Industrial hemp is legal across the United States and most of the world so that gives hemp-infused product manufacturers more freedom than cannabis product manufacturers. Being able to sell products online and ship them nationwide is a game changer, and it allows for plant-based remedies to quickly and easily reach those who need it most.”

The team at Mary’s is also breaking new ground in the scientific community as they were the first to release products with lesser known compounds of the plant including; THCa, CBN, and CBC. “We dedicate a significant amount of resources to R&D so that we’re able to stay ahead of the curve and pave the way in releasing products that target different human indications,” said Dr. Riggle.

This new era of cannabis research is great for patients and for business. Savvy small business owners like Cargile know that by providing consumers with the option of CBD products, their business can increase sales. In addition to providing a higher level of customer satisfaction, “CBD products hold a higher sales value and will give a larger return as opposed to high-THC products,” she explained.

In the past decade, the medical community has seen more cannabinoid-related studies than any other time in history. As the industry and medical communities continue to establish cannabis as medicine, it’s only a matter of time until the U.S. Government removes cannabis from it’s list of banned substances without medical benefits.

The political implications of the study aren’t lost on the authors. They wrote, “the findings also inform the ongoing medical marijuana debate concerning medical benefits of non-psychoactive cannabinoids and their promise for development and use as therapeutics.” For Dr. Riggle, the issue of marijuana legalization and the medical application of CBD are completely separate. “I’d like to think that the vast number of studies being conducted, and the mounting amount of evidence can help move the needle,” he told NCIA.


VIDEO: How Section 280E of the IRS Tax Code Burdens the Cannabis Industry

Related Posts

Join the movement

NCIA is leading the cannabis industry's unified and coordinated campaign to ensure our business sector is treated fairly and has the opportunity to reach its full potential. Now - more than ever - is the time to invest in your business and the future of the industry by becoming a member.

This site uses cookies. By using this site or closing this notice, you agree to the use of cookies and our privacy policy.